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14 months after cessation of Natalizumab
in a patient with Leber’s optic neuropathy
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Abstract
Background: Leber’s hereditary optic neuropathy (LHON) co-occuring with multiple sclerosis-like disease (LHON-MS) is
suggested to be a separate disease entity denoted Harding’s disease. Little is known about the response to initiation
and discontinuation of potent immunomodulatory treatment in LHON-MS.
Case presentation: We describe a LHON-MS patient with 27 years disease duration who developed severe disease
activity peaking 14 months after discontinuation of natalizumab, with extensive new inflammatory lesions throughout
the brain and in the spinal cord resembling immune inflammatory reconstitution syndrome. She had previously been
clinically and radiologically stable on natalizumab treatment for 6 years, and before that only experienced subtle clinical
activity during 9 years on interferon beta1a.
Conclusion: This is the first report on severe exacerbation of inflammatory disease activity after discontinuation of
natalizumab in LHON-MS, and suggests that late rebound activity can occur in these patients.
Keywords: Multiple sclerosis, Leber’s optic neuropathy, Natalizumab, Rebound, Immune reconstitution inflammatory
syndrome, Case report
Background
Leber’s hereditary optic neuropathy (LHON) is caused
by point mutations in mitochondrial DNA that encodes
complex 1 in the respiratory chain, and usually manifests
as subacute severe and painless deterioration of central
visual acuity, caused by loss retinal ganglion cells in the
papillomacular bundle [1]. The co-occurrence of LHON
and a multiple sclerosis-like disease (LHON-MS) is sug-
gested to be 50 times more frequent than expected by
chance [2], and has been considered a distinct entity
named Harding’s disease [3]. With the exception of more
frequent and severe involvement of the optic nerves
LHON-MS seems to resemble relapsing remitting (RR)
MS both clinically and radiologically [4], and most patients
also have intrathecal synthesis of immunoglobulin G [2].
Immunomodulatory treatment such as natalizumab can
therefore be considered. In MS, it is well established that
disease activity returns within 4–7 months after discon-
tinuation of natalizumab [5–7]. Some studies also reports
possible rebound activity with disease activity exceeding
pre-treatment levels or with particularly severe MS relapses
[8–10]. Very little is known about the possible effects of
starting and discontinuing potent immunomodulatory
treatment in LHON-MS.
Case presentation
The patient is born in 1965. Her first neurological symp-
tom was a subacute right sided hemiparesis with partial
recovery in 1989. In 1991 she experienced subacute and
severe loss of vision on her left eye, without pain and
with slow and incomplete recovery. The cerebrospinal
fluid contained oligoclonal immunoglobulin G without
counterpart in serum, and MS was diagnosed. In April
1992 she had subacute and pronounced loss of vision on
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her right eye, and 1 week later on the left eye (finger
counting 0.5 m on both eyes). There has later been some
fluctuation but no substantial improvement of her
central visual acuity, whereas her peripheral vision has
remained more intact. After some years her previously
healthy son presented at the age of 16 years with bilat-
eral painless sequential visual loss. Both pupils reacted
to light. He had large absolute centrocecal scotomata.
Funduscopy was unremarkable. No other neurological
abnormalities were noted. He was treated with intraven-
ous steroids followed by oral steroids without any bene-
fit. LHON was suspected and mutation of G11778a in
the ND4-gene was found. This finding resulted in fur-
ther examination of our patient, and revealed that she is
heteroplasmic (92 % mutant) for the same mutation.
Our patient reported transient ataxia with dysphagia
in 1994, and ataxia with increased fatigue in 1999.
Neurological examination in 2000 revealed spastic para-
paresis and reduced vision (finger counting on both
eyes), and interferon beta 1a (Rebif©) was initiated. She
was seen yearly by an experienced MS neurologist who
found that she was clinically stable the following years,
with Expanded Disability Severity Scale (EDSS) score at
4.0. In June 2008 the patient cancelled the planned con-
sultation because she felt she was clinically stable. She
also had regular contact with an MS nurse, and in June
2009 she called the MS nurse and reported that she had
suffered a possible mild attack with pain and transiently
reduced strength in two fingers in her right hand, and
that she wanted to discuss the possibility of switching
the treatment to natalizumab (Tysabri©). In August the
same year she again called the MS nurse and reported
paresthesia in her left lower arm. These symptoms sub-
sided after 4 weeks, again without subjective sequela.
She was seen by her neurologist in October 2009, who
found unchanged spastic paraparesis and reduced vision
without evidence of new neurological deficits compared
to previous examinations. She was able to walk 500 m
without aid and EDSS was 4.0. MRI of the brain in
November 2009 showed approximately 20 supra ten-
torial T2 lesions, the largest measuring 6 × 4 mm. There
were no contrast enhancing lesions, and no lesions in
the spinal cord. No previous MRI scans were available
for comparison.
The neurologist concluded that she had likely suffered
mild attacks without sequela in June 2008 and October
2009. For this reason, and also because the patient found
the interferon injections increasingly intolerable, natali-
zumab 300 mg monthly was started in November 2009.
The following years she reported no attacks, and yearly
MRI was stable with numerous supratentorial lesions. In
2012 she tested weakly positive (JCV index 0.5) for John
Cunningham virus antibodies (JCV Stratify©). The JCV
index is a titer equivalent that predicts the risk of
progressive multifocal leukoencephalopathy (PML) dur-
ing natalizumab treatment. Weakly positive JCV indices
(below 0.7) are estimated to be associated with a low
PML risk (possibly up to 0.3 ‰) after 49–72 months
treatment, compared to 17.0‰ in those with indices
above 1.5 [11]. Neurological examination in both July
2014 and January 2015 revealed slightly increasing ataxia
in the left arm and in both legs, although not to an ex-
tent that further affected gait distance (500 m) or EDSS
(4.0). Because neurological disability had increased
slightly in the absences of relapses since 2009, and
because MRI scans in March 2012, April 2013 and
October 2014 had not shown any new or gadolinium
enhancing lesions, secondary progression was suspected.
For this reason and because JCV index remained weakly
positive (0.47 in January 2015), the last dose of natalizu-
mab was given in January 2015. She could then walk
500 m without aid. MRI in April 2015 did not show new
or gadolinium enhancing lesions. In the absence of clin-
ical relapses or MRI activity, and because the progres-
sion was regarded as slow, no other disease modifying
treatment was started.
In June 2015 she was hospitalized with escalating gait
difficulties and could only walk a few meters even with
aid, corresponding to an estimated EDSS at 7.5. MRI of
the brain and cervical and upper thoracic spinal cord
did not show new or active lesions. She recovered some-
what (EDSS 6.0; corresponding to requirement of aid to
walk 100 m), and no treatment was given. In December
2015 she reported subacute deterioration of vision at the
left eye, with loss of finger counting. In March 2016 she
was hospitalized with increasing left-sided hemiparesis
and reduced sensation, urinary retention and dysphagia.
Movement was restricted to wheelchair, and she could
hardly raise her left arm against gravity. Compared to
the last previous MRI from June 2015, MRI showed at
least 12 new lesions in the cerebral hemispheres, two in
pons, one in the left thalamus and several in the medulla
(Fig. 1). Numerous lesions were active with gadolinium
enhancement, including in the spinal cord from C6 to
Th1. Some large and confluent lesions were susceptive
of progressive multifocal leukoencaphalopathy. Her JCV
index had increased to 1.25. A slight elevation of
albumin index and pleocytosis (8 white blood cells/μl)
was recorded in the first cerebrospinal fluid sample, but
not after 14 days. PCR for JC virus in the cerebrospinal
fluid was negative at both occasions. As PML was con-
sidered highly unlikely, and because the pronounced
contrast enhancement both in the brain and in the me-
dulla rather suggested severe and IRIS-like exacerbation
of MS she was treated with high dose methylpredniso-
lone for 5 days, followed by some clinical improvement
of the hemiparesis, dysphagia and urinary retention.
MRI 4 weeks after admission revealed marked regression
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of both confluent lesions and gadolinium enhancement
in cerebrum and medulla. In agreement with the patient
who has remained cognitively intact, treatment with
alemtuzumab was started in April 2016. Her EDSS score
peaked at 8.0 and was 6.5 in June and August 2016.
Conclusions
This case story shows that severe disease activity resem-
bling IRIS can occur after 27 years disease duration in a
patient with LHON-MS, and raises the question whether
this unusual exacerbation was triggered by the with-
drawal of natalizumab 14 month previously.
The concept of rebound disease activity upon discon-
tinuation of natalizumab in RRMS is not entirely clear.
A systematic study of relapses in RRMS patients during
the suspension of natalizumab in 2005 showed that dis-
ease activity returned to pre-natalizumab levels and
peaked between 4 and 7 months, without evidence of
rebound [6]. On the other hand, others have reported in-
creased disease activity compared to pre-treatment levels
in a substantial proportion of patients, including IRIS-
like and lethal exacerbations [5]. In most cases the pa-
tients with possible rebound had aggressive RRMS prior
to treatment with natalizumab. High risk of significant
worsening after natalizumab withdrawal has, however,
been reported also in patients with possible secondary
progressive MS with EDSS exceeding four [10], which
was one of the reasons for withdrawal in our patient.
Our patient had no MRI activity when the first clinical
signs of disease activity appeared 6 months after discon-
tinuation of natalizumab, and the full-blown IRIS-like
exacerbation first appeared after 14 months. This is lon-
ger than reported in MS [5, 9, 12]. Saturation of alpha4
integrin is permissive for the immunological effect of
natalizuamb. Desaturation to 50 % is likely to occur
when serum levels of natalizumab fall below 1 μg/ml
Fig. 1 MRI during the early phase and at the peak of post-natalizumab exacerbation. The upper panel shows Fluid inversion recovery (FLAIR;
a, b and c) and T2 (d) from June 2015. The middle panel shows examples of new and enlarging lesions on corresponding FLAIR (e, f and g) and
T2 (h) sections at March 2016. The lower panel (i, j and k) shows examples of gadolinium enhancement on T1 images at March 2016
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[13], which has been predicted to take almost 100 days
in 50 % of MS patients on long-term treatment.
Natalizumab can however be measured in the serum up
to 260 days after the last infusion, with pronounced vari-
ation between individuals [14]. Interestingly, it has been
demonstrated that natalizumab can exchange Fab-arms
with wild-type IgG4 in natalizumab-treated patients,
possibly contributing to observed variation in the elimin-
ation time [15]. It is thus possible that the time needed
to desaturation of α4-integrin varies considerably be-
tween individuals, and that an observation period of up
to 1 year after natalizumab withdrawal, as reported in
several studies [6, 8, 10], is too short to capture all cases
of possible rebound.
It must, however, also be considered whether the IRIS-
like exacerbation in our patient was not causally related
to the withdrawal of natalizumab. Because of the rarity,
there are no systematic studies of the natural history of
LHON-MS. With the exception of early and severe bilat-
eral optic neuropathy, it does however not seem to differ
very much from other patients with MS [2, 16]. Interest-
ingly, the IRIS-like MRI findings in our patient share
some features with another LHON-MS patient previ-
ously reported [17], who had not been treated with nata-
lizumab or other immunomudulatory drugs, and who
died after 19 years disease duration [18]. There are how-
ever differences, as the most prominent feature of the
previously published patient was a cystic and space-
occupying lesion in the frontal lobe and contrast enhance-
ment seemed to be less prominent than in our patient.
It is not known if or how Leber mutations contribute
to the MS-like pathology in LHON-MS, or how the con-
dition should be treated. In contrast to previous reports
[2], a recent study did not find more Leber mutations
among MS patients than expected by chance [16], thus
challenging that LHON-MS is a distinct entity. On the
other side, mitochondrial dysfunction is indeed part of the
pathogenesis in MS also in patients without LHON
[19], and mitochondrial manganese superoxide has
been reported to be upregulated in lesions outside
the optic nerves in autopsy material from a patient
with LHON-MS [18].
Given the radiological, immunological and clinical re-
semblance with MS, we find it reasonable to treat pa-
tients with LHON-MS with immunomodulatory drugs
as other patients with MS. The current case report un-
derscores the need to be cautious when considering
withdrawal of natalizumab also in these patients, and
suggests that severe rebound activity can occur more
than a year after natalizumab withdrawal.
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